{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"64.3","upperLimit":"90.4","value":"76.3"},{"groupId":"OG001","lowerLimit":"67.4","upperLimit":"95.4","value":"80.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"52"},{"groupId":"OG001","value":"48"}],"units":"Participants"}],"description":"Time from first response of CR/CRi to the first of event or censoring, in responders.\n\nCohort A: Events = Relapse or Death; Censoring = Initiation of New Anticancer Therapy, Last Day of Follow-up/EOS; whichever occurs first.\n\nCohort B: When defining responders, CR/CRi without B Cell Aplasia is considered no response. Events = Relapse or Death; Censoring = Initiation of New Anticancer Therapy, Last Day of Follow-up/EOS; whichever occurs first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with newly diagnosed VHR B-ALL or high-risk relapse of B-ALL","id":"OG000","title":"Cohort A"},{"description":"Patients with poor response to prior B cell directed engineered cell therapy","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"1 year","title":"Percentage of Subjects With Relapse-free Survival","type":"SECONDARY","unitOfMeasure":"percentage of subjects"}